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     RESPONSE TO CHEMOTHERAPY IN ENDOCRINE
THERAPY－RELAPSED AND 一RESISTANT PROSTATE CANCER
Susumu Akimoto， Koichiro Akakura， Motoyuki Masai
            and Jun Shimazaki
Fro〃3 the DePartt’leng’（プUrogogy， SahoolげMedicine， Chiba｛ノノt icrersめ’
  Effects of chemotherapy to endocrine therapy （castration with estrogen！antlandrogerr）一relapsed
（21 cases） or endocrine therapy－resistant （14 cases） prostate cancer were compared． Pretr．eatment
clinical stages in these groups were stage Dl （3 cases）and D2 （35 cases）． Reglmens of chemother－
apy in thi’s study were as． follows ： cis－platinum （CDDP） （1 case）， ifosphamide （8 cases）， combina－
tion of vincristine， ifosphamide and peplomycin （5 cases）， combination of cyclQphosphamlde，
adriamycine （ADM） and CDDP （8 cases） and combinatiolt of ifosphamide， ADM and CDDP （21
cases）． Response to chemotherapy and subsequent survival in these two groups were examined．
  When evaluated at 3 months after the start Qf the chemgtherapy，．partlal response and stable
cases were 50％o ’≠獅?36MO in endocr．ine therapy－relapsed and 一resistant groups， respectively． Because
the worse performarice status contained more cases in the’?獅р盾モ窒撃獅?th rapy－resista．nt group， the
response was compared at the same base o｛i performance s．tatus・， and the response Was almost
eclual in the two groups， Survival in the endocrine therapyLrelapsed group was better than that
in the therapy－reg．istant group． When cQmpared at the same base of performance status， the differ－
ence in survival time between the two greups was not eviderit．．
  1’n conclusion， the response of chemotherapy was similar between endocrine therapy－relapsed
and 一resistant patients， and per’formance status was a main i’actor infiuencing the prognosis ofendo－
c．rine therapy－refractory prostate． cancer．
                                      （Acta Urel． Jpn． 37： 31－37， 1991）
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Table 1． Regimens of initial chemotherapy
CDDP lfosphamide




隔1鱒㎝vcin   smgX6
Cyc唇opho印hamide  謄05ph8mきde  loomgX5 2g X 3Adriemycin Adriamycin
   釦rng      30mg CDDP semg CDDP 50mg
retapsed“    lb
 （24）
2 3c 6d．e．g 12f・h














































































































































Table ‘5， Response judged by criteria described by Akaza et al．8）
Primety         overallbone crthers PAP         response
    CR   O
    PR   3relapsed   Stable 21
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PD ： Progressive Diseese
Table 4． Changes of performance status （PS），
     pain and dysuria
Table 5． Performance status
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relapsed resistantO．1
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Table 6．Relationship between performance
















   O 10 20 30 40     Months after start of chemotherapy
Fig． 1． Survlval after start of chemotherapy to
    endocrine therapy－reiapsed and 一resistant
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Fig． 4．
o
Survival after start of chemotherapy as
a function of performance status
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O 10 20 30 40  Menths after start ot chemotherapv
Fig． 3． Effects of difl；erent types of chemo－
     therapy on survival of endocrlne therapy－
     relapsed patients























































ADM，5－FU併用23）， CDDP， CPM， Pep併用24），
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